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http://dx.doi.org/10.1016/j.stemcr.2016.08.015SUMMARYNeural stem/progenitor cells (NS/PCs) derived from human induced pluripotent stem cells (hiPSCs) are considered to be a promising cell
source for cell-based interventions that target CNS disorders. We previously reported that transplanting certain hiPSC-NS/PCs in the
spinal cord results in tumor-like overgrowth of hiPSC-NS/PCs and subsequent deterioration of motor function. Remnant immature cells
should be removed or induced into more mature cell types to avoid adverse effects of hiPSC-NS/PC transplantation. Because Notch
signaling plays a role in maintaining NS/PCs, we evaluated the effects of g-secretase inhibitor (GSI) and found that pretreating hiPSC-
NS/PCs with GSI promoted neuronal differentiation and maturation in vitro, and GSI pretreatment also reduced the overgrowth of
transplanted hiPSC-NS/PCs and inhibited the deterioration of motor function in vivo. These results indicate that pretreatment with
hiPSC-NS/PCs decreases the proliferative capacity of transplanted hiPSC-NS/PCs, triggers neuronal commitment, and improves the safety
of hiPSC-based approaches in regenerative medicine.INTRODUCTION
Embryonic stem cells and induced pluripotent stem cells
(iPSCs) can differentiate into neural stem/progenitor cells
(NS/PCs), which can subsequently be induced in vitro to
differentiate into threeneural lineages: neurons, astrocytes,
and oligodendrocytes (Falk et al., 2012; Miura et al., 2009;
Okada et al., 2004). Furthermore, accumulating evidence
suggests that NS/PCs represent a promising cell source for
regenerative medicine targeting CNS disorders (Cummings
et al., 2005; Hofstetter et al., 2005; Iwanami et al., 2005; Ku-
magai et al., 2009;Nori et al., 2011;Okada et al., 2005, 2008;
Ogawa et al., 2002; Salazar et al., 2010; Yasuda et al., 2011).
Our previous reports have shown that transplantation of
NS/PCsderived fromhuman inducedpluripotent stemcells
(hiPSC-NS/PCs) promotesmotor function recovery in non-
obese diabetic-severe combined immune-deficient (NOD-
SCID) mice and non-human primates with spinal cord
injury (SCI) (Fujimoto et al., 2012; Kobayashi et al., 2012;
Nori et al., 2011;Okano et al., 2013; Tsuji et al., 2010). How-
ever, transplanting certain hiPSC-NS/PCs, such as clone
253G1 (generated through a process of retroviral transfec-
tion), results in tumor-like overgrowth and deterioration
of motor function during long-term observations (Nori
et al., 2015), and transplanting clone 836B3 (episomal
plasmid vectors) in an SCI animal model yielded similar
results during long-term observations (our unpublished
data).Moreover, these tumors consisted of undifferentiated
human-specific Nestin+ cells.Stem Cell Re
This is an open access artiThe safety of measures for preventing tumor-like over-
growth is of great importance in clinical applications of
iPSC-based transplantation therapy for SCI. Remnant
immature NS/PCs must be removed or induced to differen-
tiate into more mature cell types, which may avoid tumor-
like overgrowth following transplantation. Notch signaling
controls the induction of NS/PCs, and inhibition of this
signaling with a g-secretase inhibitor (GSI) induces the
NS/PCs todevelop intoamoremature statewith limitedpro-
liferation invitro (CrawfordandRoelink,2007;Nelsonet al.,
2007). Treatment of iPSC-derived dopaminergic progenitor
cells with GSIs prior to transplantation into the normal
mid-striatumis knowntocontrol thegrowthof apotentially
proliferative cell population in vivo (Ogura et al., 2013).
The purpose of the present study was to elucidate the ef-
fects of a GSI on the proliferation and differentiation of
tumorigenic hiPSC-NS/PCs in vitro, assess the effects of
GSI pretreatment on the hiPSC-NS/PCs in vivo, and
determine whether animalmodels of SCI exhibit recovered
motor functions and an absence of tumor-like overgrowth
following transplantation of the pretreated cells.RESULTS
Treatmentwith theGSI Suppressed the Proliferation of
hiPSC-NS/PCs
We performed differentiation and proliferation assays us-
ing hiPSC-NS/PCs in vitro. After treating the cells withports j Vol. 7 j 649–663 j October 11, 2016 j ª 2016 The Author(s). 649
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Figure 1. Proliferation of hiPSC-NS/PCs
Treated with or without GSI
(A) Number of living cells counted in ten
separate fields using a microscope and
compared among each group (n = 5 indepen-
dent experiments).
(B) Micrographs showing representative
hiPSC-NS/PC aggregates for each group and
cell line. Scale bars, 200 mm.
(C) Size of hiPSC-NS/PCs measured in ten
separate fields using a microscope and
compared among each group (n = 5 indepen-
dent experiments).
(D) Cell-cycle analyses of hiPSC-NS/PCs per-
formed using flow cytometry. Representative
dot plots are shown for each group.
(E) Histograms show the relative distribution
of hiPSC-NS/PCs across the different cell cycle
phases under self-renewing conditions (n = 5
independent experiments).
(F) Analyses of hiPSC-NS/PC apoptosis per-
formed using the annexin V/7-AAD apoptosis
assay. The histograms show the relative dis-
tribution of hiPSC-NS/PCs across the different
phases (n = 5 independent experiments).
*p < 0.05, **p < 0.01, and not significant
(N.S.) according to one-way ANOVA with the
Tukey-Kramer test. Data are presented as
means ± SEM.or without GSI, aggregated hiPSC-NS/PCs were dissociated
into single cells and the living cells were counted. In the
GSI-4d group (hiPSC-NS/PCs cultured in vitro with GSI
for 4 days), the number of living cells was significantly
decreased compared with that of the other groups
(253G1: control 1.14 3 106 cells, GSI-1d [hiPSC-NS/PCs
cultured in vitro with GSI for 1 day] 9.80 3 105 cells,
GSI-4d 7.28 3 105 cells; 836B3: control 1.51 3 106 cells,
GSI-1d 1.31 3 106 cells, GSI-4d, 8.42 3 105 cells;
Figure 1A). Next, the size of the sphere was measured
by microscopy after treatment with or without GSI.
In the control group, the size of the sphere was sig-
nificantly increased compared with that of both GSI
groups (253G1: control 394.7 ± 69.5 mm, GSI-1d 224.1 ±
46.1 mm, GSI-4d 220.4 ± 17.3 mm; 836B3: control
155.2 ± 10.7 mm, GSI-1d 110.4 ± 23.6 mm, GSI-4d
105.9 ± 21.8 mm; Figures 2B and 2C).650 Stem Cell Reports j Vol. 7 j 649–663 j October 11, 2016In the cell-cycle analyses, representative dot plots of the
flow cytometry data revealed a reduced S-phase population
among the GSI-treated hiPSC-NS/PCs (Figure 1D).
Compared with the control group, the proportion of cells
in G0/G1 phase was significantly increased (253G1: control
62.6% ± 2.7%, GSI-1d 72.8% ± 1.1%, GSI-4d 74.8% ±
1.8%; 836B3: control 58.9% ± 1.3%, GSI-1d 74.4% ±
2.3%, GSI-4d 75.7% ± 2.9%). The proportion of cells in
the S phase was significantly decreased in both GSI groups
(253G1: control 18.6% ± 0.8%, GSI-1d 4.1% ± 0.2%,
GSI-4d 3.6% ± 0.1%; 836B3: control 33.8% ± 0.9%,
GSI-1d 9.6% ± 0.6%, GSI-4d 11.2% ± 1.2%; Figure 1E).
According to the annexin V/7-AAD apoptosis assay, the
proportion of early apoptotic cells was slightly increased
in both GSI groups compared with the control group,
although significant differences were not observed
among these groups (253G1: control 2.01% ± 0.2%,
GSI-1d 4.1% ± 0.3%, GSI-4d 5.5% ± 0.4%; 836B3: control
2.0% ± 0.5%, GSI-1d 3.1% ± 0.3%, GSI-4d 4.7% ± 0.5%).
These results suggest that GSI treatment could induce the
differentiation of undifferentiated hiPSC-NS/PCs.
GSI Induced Differentiation into More Mature
Neuronal Cell Types with Limited Cell Proliferation
Next, we assessed the effects of GSI on the neuronal differ-
entiation and maturation of hiPSC-NS/PCs. In both GSI
groups, the proportion of Ki-67+ (a cell proliferation
marker) and Nestin+ (a neural stem cell marker) cells was
also significantly decreased compared with that of the con-
trol group (Ki-67+ cells: 253G1—control 45.2% ± 1.4%,
GSI-1d 30.7% ± 2.2%, GSI-4d 28.1% ± 0.8%; 836B3—con-
trol 34.0% ± 2.7%, GSI-1d 16.7% ± 1.9%, GSI-4d 13.0% ±
1.7%; Nestin+ cells: 253G1—control 60.8% ± 1.9%, GSI-
1d 36.6% ± 1.2%, GSI-4d 30.9% ± 1.4%; 836B3—control
43.6% ± 2.1%, GSI-1d 34.1% ± 0.5%, GSI-4d 23.6% ±
1.1%; Figures 2A–2D), whereas the proportion of bIII-tubu-
lin+ neurons was significantly increased (253G1: control
70.9% ± 2.3%, GSI-1d 94.7% ± 3.1%, GSI-4d 94.3% ±
2.4%; 836B3: control 47.6% ± 4.8%, GSI-1d 86.0% ±
4.9%, GSI-4d 86.7% ± 5.0%). The proportion of GFAP+
astrocytes and CNPase+ (20,30-cyclic-nucleotide 30-phos-
phodiesterase) oligodendrocytes was not significantly
different among the three groups (Figures 2E–2H). Micro-
electrode array (MEA) analyses indicated that neuronal
maturation was significantly enhanced in both GSI groups
compared with the control group (Figure 2J).
Gene Expression Profiles of hiPSC-NS/PCs after the
GSI Treatment
DNA microarray analyses were performed on the hiPSC-
NS/PCs that were treated with or without GSI to evaluate
the gene expression profiles of the cells. Following the GSI
treatment, 61 genes were downregulated (downregula-
tion: 97 genes in the GSI-1d group, 274 genes in the
GSI-4d group; Figure 3A) and 53 genes were upregulated
(upregulation: 58 genes in the GSI-1d group, 147 genes
in the GSI-4d group; Figure 3B) in 253G1 hiPSC-NS/PCs.
In 836B3 hiPSC-NS/PCs, 26 genes were downregulated
(downregulation: 49 genes in the GSI-1d group, 63 genes
in the GSI-4d group; Figure 3C) and seven genes were
upregulated (upregulation: eight genes in the GSI-1d
group, 77 genes in the GSI-4d group; Figure 3D). Func-
tional association analyses showed that the expression
of cell-cycle-related genes and more mature neuronal
marker-related genes increased by >2-fold in both GSI
groups compared with the control group. Significant in-
creases in the levels of p53-dependent genes, such as
CDKN1C and GADD45G, and more neuronal matura-
tion-dependent genes, such as NEUROG1, NEUROD1,
and ASCL1, were detected (Figures 3E and 3F).Gene Ontology (GO) analyses identified a number of
neuronal differentiation- andmaturation-associated terms,
such as ‘‘neuron differentiation,’’ ‘‘neuron development,’’
‘‘developmental maturation,’’ ‘‘regulation of cell cycle,’’
and ‘‘neuron projection development,’’ in the GSI-treated
hiPSC-NS/PCs (Tables S1 and S2).
We performed RT-PCR to validate these findings,
which showed that the expression of representative
Notch signaling target genes, such as HES5 and NOTCH1,
was nearly abolished by pretreatment with GSI
(Figure S1A). In addition, the expression of early neural
marker genes, such as SOX2 and PAX6, was also downre-
gulated in both GSI groups. The expression of mature
neuronal marker genes, such as NEUROG2, ASCL1, and
NEUROD1 (but not glial markers, such as GFAP and
OLIG2), was upregulated, as expected, given the down-
regulated expression of pluripotency/self-renewal
markers, such as NANOG, LIN28, OCT4, and NESTIN
(Figures S1B–S1D).
Next, we confirmed the role of Notch signaling in the
specification of hiPSC-NS/PCs by comparing the qRT-
PCR analyses for each cell line after treatment with or
without GSI. The data were presented as expression levels
relative to the 836B3 hiPSC-NS/PCs. The expression
of Notch signaling-related genes, such as JAGGED1,
NOTCH1, and PSEN1, was significantly upregulated in
the 253G1 hiPSC-NS/PCs, which seemed to indicate
that Notch signaling was increased in the 253G1 hiPSC-
NS/PCs compared with the 836B3 hiPSC-NS/PCs. Under
these activation conditions, the expression of the HES5,
HEYL, HSPB1, ID2, ID4, NESTIN, OCT3/4, VCAM1, and
NANOG genes were particularly downregulated in the
GSI-treated groups compared with the control group.
Additionally for each cell line, the GSI treatment resulted
in a decrease in the expression of the target genes of
Notch signaling, such as JAGGED1 and NRARP (Figures
S2A and S2B).
Previous transcriptome analyses by our group revealed
the altered expression of genes involved in epithelial-
mesenchymal transition (EMT), which plays roles in tumor
invasion and progression, following the transplantation of
253G1 hiPSC-NS/PCs (Nori et al., 2015). The expression of
EMT-related genes, such as SNAIL1, SNAIL2, TWIST1, and
TWIST2, was downregulated in the GSI-treated group
compared with the control group (Figure 3G).
Long-Term Observations after Transplantation of
Tumorigenesis-/Overgrowth-Prone hiPSC-NS/PCs
that Had Been Pretreated with GSI
Next, we examined the long-term effects of GSI pretreat-
ment on hiPSC-NS/PCs that had been transplanted into
SCI model mice in vivo and focused on the potency
of the GSI treatment in preventing the tumor-likeStem Cell Reports j Vol. 7 j 649–663 j October 11, 2016 651
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Figure 2. Neuronal Differentiation and Neuronal Maturation of hiPSC-NS/PCs Treated with or without GSI
(A and B) hiPSC-NS/PCs (with or without GSI treatment) dissociated into single cells, seeded on coverglasses, and immunostained for
Ki-67 (cell proliferation marker) and Nestin (a neural stem cell marker). The nuclei were stained with Hoechst 33258. The micrographs show
representative staining results for each group. Scale bars, 50 mm.
(C and D) Histograms showing the percentage of Ki-67+ and Nestin+ cells (n = 5 independent experiments).
(legend continued on next page)
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overgrowth of the graft-derived cells. A previous study by
our group showed that 253G1 hiPSC-NS/PCs are charac-
terized by tumor-like overgrowth following cell transplan-
tation in the injured spinal cord of NOD/SCID mice (Nori
et al., 2015). In fact, 253G1 hiPSC-NS/PCs tended to grow
and spread at a faster rate than 836B3 hiPSC-NS/PC tra-
nsplants (our unpublished data). Here, we found that
inhibiting Notch signaling with the GSI promoted the
neuronal differentiation and maturation of hiPSC-NS/
PCs in vitro, irrespective of the culture period and the
cell line (Figure 2). Thus, we pretreated the 253G1
hiPSC-NS/PCs with the GSI for 1 day before cell trans-
plantation. To monitor the survival and growth of the
transplanted cells in the mouse injured spinal cord, we
lentivirally transduced the hiPSC-NS/PCs with ffLuc, a
fusion protein between a fluorescent protein Venus and
a firefly luciferase (Hara-Miyauchi et al., 2012), which
allowed us to identify the transplanted cells by their
bioluminescent luciferase signals and fluorescent Venus
signals. The photon counts and the number of the
hiPSC-NS/PCs were significantly correlated (r2 = 0.998,
Figures S3A–S3C). The photon counts of the transplanted
hiPSC-NS/PCs decreased within the first 7 days, although
they gradually increased at 14 days after cell transplanta-
tion. In the control group, the photon counts were prom-
inently increased compared with that of the GSI+ group
between 28 and 89 days after cell transplantation (Figures
4A and 4B). The photon counts of the control group
increased more than 10-fold from their initial values at
89 days after cell transplantation. In the GSI+ group, the
photon counts increased more slowly and reached a
plateau at 28 days after cell transplantation. Representa-
tive results of H&E staining of spinal cords from the
control group and the GSI+ group after injury and trans-
plantation are shown in Figure 4C. In the control group,
the HNA+ transplanted cells occupied the entire spinal
cord, whereas the cells in the GSI+ group did not. The
volumes and sizes of the grafts that were pretreated with
GSI were significantly smaller than the grafts in the con-
trol group (volume of grafts: control group 7.3 ±
1.5 mm2, GSI+ group 1.3 ± 0.6 mm2; Figures 4D and
4E). After transplantation into the injured spinal cord,
the transplanted hiPSC-NS/PCs differentiated into three
neural lineages in each group, such as pan-ELAVL (Hu)+
neurons, GFAP+ astrocytes, and APC+ oligodendrocytes.(E and F) Fourteen days after neuronal induction, the hiPSC-NS/PC
(an astrocyte marker), and CNPase (an oligodendrocyte marker). Th
representative staining results for each group. Scale bars, 50 mm.
(G–I) Histograms showing the percentage of bIII-tubulin+, GFAP+, an
(J) Daily analyses of neuronal maturation using MEA, which measures t
*p < 0.05, **p < 0.01, and not significant (N.S.) according to on
means ± SEM.We also detected the Ki-67+ and Nestin+ cells (Figure 4F).
Immunostaining for various cell markers was examined
89 days after transplantation and subjected to quantita-
tive analyses to evaluate the differentiation phenotype
of the transplanted cells in vivo. The proportion of pan-
ELAVL (Hu)+ cells was significantly increased (control
group 15.6% ± 1.2%, GSI+ group 51.0% ± 1.8%) in the
GSI+ group, although the proportion of Ki-67+ cells (con-
trol group 17.9+ ± 0.9%, GSI+ group 3.9% ± 0.9%) and
that of Nestin+ cells (control group 30.3% ± 1.6%, GSI+
group 5.3% ± 0.8%) were also significantly decreased
compared with the control group. The proportion of
GFAP+ cells (control group 15.6% ± 1.1%, GSI+ group
11.5% ± 3.9%) and that of APC+ cells (control group
5.2+ ± 1.1%, GSI+ group 4.2% ± 1.0%) were not signifi-
cantly different between the control group and the
GSI+ group (Figure 4G).
We examined triple immunostaining with HNA, bIII-tu-
bulin, and mouse-specific Bassoon (Bsn), a presynaptic
marker, to evaluate the ability of the GSI-pretreated trans-
planted cell-derived neurons to integrate with host neural
circuitry. bIII-tubulin+/HNA+ cells that were transplanted
in parenchymal locations were contacted by Bsn+ synaptic
boutons of the host neurons (Figure S4A). Moreover, triple
immunostaining for HNA, bIII-tubulin, and human-spe-
cific synaptophysin (hSyn) revealed that hSyn+ boutons
apposed the host mouse neurons (bIII-tubulin+/HNA)
(Figure S4B). Furthermore, immunostaining for Notch1,
activated Notch1, and Snail were examined 89 days after
transplantation and subjected to quantitative analyses to
confirm the level of Notch activation and EMT in the
transplanted cells in vivo. In the GSI+ group, the pro-
portion of Notch1+ cells (control group 43.1% ± 7.2%,
GSI+ group 2.5% ± 2.3%), activated Notch1+ cells (control
group 34.1% ± 3.2%, GSI+ group 0.55% ± 0.35%), and
Snail+ cells (control group 36.7% ± 5.1%, GSI+ group 0%)
were all significantly decreased compared with that of the
control group (Figures 5A–5F).
Transplantation of Tumorigenesis-/Overgrowth-Prone
hiPSC-NS/PCs Pretreated with GSI Maintains Motor
Functional Recovery after SCI
We evaluated locomotor function using the Basso Mouse
Scale (BMS) score, rotarod testing, and treadmill gait ana-
lyses with the DigiGait system. In the control group, thes were immunostained for bIII-tubulin (a neuron marker), GFAP
e nuclei were stained with Hoechst 33258. The micrographs show
d CNPase+ cells (n = 5 independent experiments).
he active electrodes in each group (n = 5 independent experiments).
e-way ANOVA with the Tukey-Kramer test. Data are presented as
Stem Cell Reports j Vol. 7 j 649–663 j October 11, 2016 653
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Figure 3. DNA Microarray and RT-PCR Ana-
lyses of GSI-Treated hiPSC-NS/PCs
(A) Venn diagrams showing the human genes
with decreased expression in each group of
GSI-treated 253G1 hiPSC-NS/PCs. Color key:
red, 36 genes with decreased expression in the
GSI-1d group; blue, 213 genes with decreased
expression in the GSI-4d group; purple, 61
genes with decreased expression in both
groups (n = 3 independent experiments).
(B) Venn diagrams showing the human genes
with increased expression in each group of
GSI-treated 253G1 hiPSC-NS/PCs. Color key:
red, 5 genes with increased expression in the
GSI-1d group; blue, 94 genes with increased
expression in the GSI-4d group; purple, 53
genes with increased expression in both
groups (n = 3 independent experiments).
(C) Venn diagrams showing the human genes
with decreased expression in the GSI-1d and
GSI-4d group of 836B3 hiPSC-NS/PCs. Color
key: red, 23 genes with decreased expression
in the GSI-1d group; blue, 37 genes with
decreased expression in the GSI-4d group;
purple, 26 genes with decreased expression in
both groups (n = 3 independent experiments).
(D) Venn diagrams showing the human genes
with increased expression in the GSI-1d and
GSI-4d groups of 836B3 hiPSC-NS/PCs. Color
key: red, 1 gene with increased expression in
the GSI-1d group; blue, 70 genes with
increased expression in the GSI-4d group;
purple, 7 genes with increased expression in
both groups (n = 3 independent experiments).
(E and F) (E) Lists showing the downregulated
and (F) upregulated genes compared with
control and GSI-1d and GSI-4d groups for
each cell line using DNA microarrays (fold
change >2.0).
(G) qRT-PCR analyses of known EMT-related
genes in the GSI-1d and GSI-4d groups
compared with the control group (equal to 1).
The data were normalized to the reference
GAPDH levels (n = 3 independent experi-
ments). *p < 0.05 and **p < 0.01 according to
one-way ANOVA with the Tukey-Kramer test.
Data are presented as means ± SEM.
See also Figure S1.recovery of motor function persisted for up to 35 days af-
ter transplantation, although thereafter hindlimb motor
function exhibited gradual deterioration according to
the BMS score. In the GSI+ group, significantly greater
functional recovery was observed relative to the PBS
group and the control group at 42 days after transplanta-
tion and was maintained thereafter (Figure 6A). The gait
performance of the mice in each group was analyzed us-654 Stem Cell Reports j Vol. 7 j 649–663 j October 11, 2016ing the rotarod test and the DigiGait system at 89 days af-
ter transplantation. In the GSI+ group, the mice remained
on the rotating rod for a significantly longer time than the
mice in the PBS group and the control group (Figure 6B),
and all of the mice could sufficiently walk on a treadmill
at 7 cm/s to perform the test. The gait analyses also re-
vealed a significantly longer stride length in the GSI+
group than in the PBS and control groups (Figure 6C).
Transplantation of Normal/Safe hiPSC-NS/PCs
Pretreated with GSI Survive and Enhance Motor
Functional Recovery Following SCI
Finally, we elucidated the long-term effects of GSI pre-
treatment on normal/safe hiPSC-NS/PCs that were trans-
planted into SCI model mice. Our group previously
showed that 201B7 hiPSC-NS/PCs are ‘‘normal/safe’’ cell
lines that did not display tumor-like overgrowth following
transplantation in the injured spinal cord of NOD/SCID
mice (Nori et al., 2011, 2015). We transplanted 201B7
hiPSC-NS/PCs with and without GSI treatment and exam-
ined their behavior after transplantation. The photon
counts reached a plateau at 14 days after cell transplanta-
tion in each group (Figures 7A and 7B). The volume and
size of the grafts were not significantly different between
the control group and the GSI+ group (graft volume:
control group 2.2 ± 0.5 mm2, GSI+ group 2.1 ±
0.5 mm2; Figures 7C–7E). In each group, the transplanted
hiPSC-NS/PCs survived and did not cause tumor-like
overgrowth. We examined the effects of transplantation
for hiPSC-NS/PCs with and without GSI treatment on
axonal regrowth after SCI by immunostaining analyses.
More neurofilament 200-kDa-positive neuronal fibers
and 5-hydroxytryptamine-positive serotonergic fibers
were observed in the GSI+ group than in the PBS and con-
trol groups (Figures S5A and S5B). In the GSI+ group, there
were also significantly more growth-associated protein
43-positive fibers in the ventral region 1 mm caudal to
the lesion epicenter than in the PBS and control groups
(Figures S5C and S5D).
The recovery of motor function persisted for up to
89 days after transplantation in each group compared
with the PBS group. Furthermore, in the GSI+ group, signif-
icantly greater functional recovery occurred compared
with the control group at 35 days after transplantation (Fig-
ure 7F). In the GSI+ group, the mice remained on the
rotating rod for a significantly longer time those in the
PBS and control groups (Figure 7G). In the treadmill gait
analyses, significant differences were not observed in stride
length between the control group and the GSI+ group
(Figure 7H).DISCUSSION
In the present study, we report seven major findings. First,
after the hiPSC-NS/PCswere treatedwith theGSI, the num-
ber of cells, the size of neurospheres, the proportion of cells
in the S phase of the cell cycle, and the number of Ki-67+
and Nestin+ cells determined by immunostaining were all
significantly decreased compared with that of the control
group. Second, the proportion of bIII-tubulin+ neuronal
cells was significantly increased in the GSI-treated groupcompared with the control (Figure 1), and an MEA assay
showed that the average number of active electrodes
occurred significantly earlier and exhibited much more
neuronal activity than the control group (Figure 2J). Third,
the gene expression profiles of the GSI-treated hiPSC-NS/
PCs obtained from the DNA microarray and RT-PCR
showed that the expression of cell-cycle-related genes,
mature neuronalmarker-related genes, and p53-dependent
genes was increased compared with that of the control
group, which is consistent with decreases in pluripotency
and self-renewal marker genes (Figure 3). Fourth, after
transplantation of the hiPSC-NS/PCs in animal models of
SCI, the photon counts of the transplanted cells increased
more slowly and reached a plateau at 28 days in the GSI+
groups as determined by bioluminescence (BLI) (Figures
4A and 4B). Fifth, in the GSI+ group, the proportion of
pan-ELAVL (Hu)+ cells was significantly increased,
although the proportion of Ki-67+ cells, Nestin+ cells,
Notch1+ cells, activated Notch1+ cells, and Snail+ cells
was significantly decreased compared with that of the
control group (Figures 4 and 5). Sixth, in the long-term ob-
servations, the control group showed deteriorated motor
function accompanied by tumor-like overgrowth. How-
ever, the GSI+ group maintained functional recovery and
reduced the overgrowth of transplanted cells by inhibiting
cell proliferation (Figure 6). Seventh, after transplantation
of a normal/safe cell line, the grafts that were pretreated
with GSI also survived and did not show tumor-like over-
growth, which caused motor functional recovery after
SCI (Figure 7). Taken together, these results suggest that
the GSI treatment induces the differentiation of hiPSC-
NS/PCs into a more mature state with limited proliferation
and contributes to functional recovery without tumor-like
overgrowth in the injured spinal cord. We believe that this
strategy improves the safety of hiPSC-NS/PC transplanta-
tion therapy for SCI.
Previous studies have reported that Notch signaling con-
trols the induction of neural stem cells in vitro and in vivo
during differentiation (Crawford and Roelink, 2007;
Nelson et al., 2007). As established by Ogura et al. (2013),
inhibition of this signaling pathway promotes the
neuronal differentiation of neural progenitor cells derived
from human iPSCs. Our in vitro experiments confirmed
that by inhibiting Notch signaling with the GSI, a greater
number of NS/PCs derived from two lines of human iPSCs
with tumorigenesis-/overgrowth-prone characters (253G1
and 836B3) are induced to undergo neuronal differentia-
tion and maturation, although they present limited
proliferation.
Nelson et al. (2007) showed treatments with a GSI
(DAPT) lasting at least 6 hr commits NS/PCs to neuronal
differentiation, although HES5 expression is reduced after
3 hr. In the present study, significant differences were notStem Cell Reports j Vol. 7 j 649–663 j October 11, 2016 655
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Figure 4. Long-Term Observation after Transplantation of GSI-Pretreated 253G1 hiPSC-NS/PCs
(A) Quantitative analyses of the photon counts derived from the transplanted cells until 89 days post transplantation (control group,
n = 10 mice; GSI+ group, n = 10 mice).
(B) Representative images of mice at 0, 14, 28, 56, and 89 days after transplantation of 253G1 hiPSC-NS/PCs that were pretreated with or
without GSI.
(C) Representative H&E-stained images of the spinal cord from each group at 89 days after transplantation. Scale bars, 1,000 mm.
(legend continued on next page)
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Figure 5. Level of Notch and EMT Activa-
tion in the Transplanted Cells Following
Long-Term Observations In Vivo
(A–C) Representative images of immuno-
histochemical staining show the results for
each group. The HNA+ transplanted cells
were stained with Notch1, activated
Notch1, and Snail. Scale bars, 20 mm.
(D–F) Histograms showing the percentages
of cell-type-specific, marker-positive cells
among the HNA+ transplanted cells at
89 days after transplantation (control
group, n = 10 mice; GSI+ group, n = 10
mice). **p < 0.01 according to the Wilcoxon
rank-sum test. Data are presented as
means ± SEM.observed between the GSI-1d and GSI-4d group in hiPSC-
NS/PC proliferation and differentiation, suggesting that
inhibition of Notch signaling with a GSI promotes the
neuronal differentiation and maturation of hiPSC-NS/PCs
regardless of the culture period or cell lines.
Nori et al. (2011) showed that the 201B7 hiPSC-NS/PC-
transplanted group exhibited significantly better func-
tional recovery than the PBS-injected group more than
21 days after SCI as measured by the BMS score. In this
study, the GSI+ group of 253G1 hiPSC-NS/PC transplants
(‘‘bad’’ clone) exhibited confirmed functional recovery
more than 21 days after SCI (BMS score: PBS group 2.5 ±
0.3 at 12 days post transplantation and 3.0 ± 0.1 at(D) Representative immunohistological images of HNA+ cells showing
1,000 mm.
(E) Graft volumes of hiPSC-NS/PCs were measured and estimated for
n = 10 mice; GSI+ group, n = 10 mice).
(F) Representative images of the immunohistochemical staining show
with Ki-67, Nestin, pan-ELAVL (Hu), GFAP, and APC. Scale bar, 20 mm
(G) Percentages of cell-type-specific, marker-positive cells among th
group, n = 10 mice; GSI+ group, n = 10 mice).
*p < 0.05, **p < 0.01, and not significant (N.S.) according to one-wa
(A and E). Data are presented as means ± SEM.89 days post transplantation; GSI+ group 3.8 ± 0.7 at
12 days post transplantation and 4.8 ± 0.4 at 89 days post
transplantation). Borghese et al. (2010) showed that the
neural stem cell derived from human embryonic cells
pretreated with DAPT were strongly positive for human
synaptophysin, and exhibited strong human doublecortin
staining compared with untreated cells after transplanta-
tion. In this study, the GSI+ group of 201B7 hiPSC-NS/PC
transplants (‘‘good’’ clone) exhibited a significantly greater
tendency to enhance the axonal regrowth in the mouse
injured spinal cord, which are likely to have resulted in
improved motor function compared with the control
group at 26 days after transplantation. The improveda graft from each group at 89 days after transplantation. Scale bars,
each group of SCI at 89 days after transplantation (control group,
the results for each group. The HNA+ transplanted cells were stained
.
e HNA+ transplanted cells at 89 days after transplantation (control
y ANOVA with the Tukey-Kramer test (G) or Wilcoxon rank-sum test
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Figure 6. Long-Term Motor Function
Analyses after Transplantation of GSI-
Pretreated hiPSC-NS/PCs
(A) Comparison of the BMS scores among
the PBS, control, and GSI+ groups. Motor
function in the hind limbs was assessed
weekly for up to 89 days after trans-
plantation using the BMS score (PBS group,
n = 10; control group, n = 10; GSI+ group,
n = 10 mice).
(B) Comparison of the rotarod test among
the PBS, control, and GSI+ groups. The
rotarod test was performed at 89 days after
transplantation. Histograms show the total
run time (PBS group, n = 10; control group,
n = 10; GSI+ group, n = 10 mice).
(C) Comparison of the stride lengths among
the PBS, control, and GSI+ groups. Treadmill
gait analyses were performed at 89 days
after transplantation using the DigiGait
system. Histograms show the stride length
(PBS group, n = 10; control group, n = 10;
GSI+ group, n = 10 mice).
*p < 0.05, **p < 0.01, and not significant
(N.S.) according to two-way repeated-
measures ANOVA with the Tukey-Kramer test
(A) or one-way ANOVA with the Tukey-
Kramer test (B and C). Data are presented as
means ± SEM.motor function was maintained after this point in the GSI+
group (BMS score: control group 3.8 ± 0.2 at 26 days post
transplantation and 4.4 ± 0.5 at 89 days post transplanta-
tion; GSI+ group 4.3 ± 0.5 at 26 days post transplantation
and 4.9 ± 0.3 at 89 days post transplantation). It is possible
that pretreatment with GSI might have other mechanisms
besides axonal regrowth, and could have a clinically mean-
ingful effect and improve human iPSC-based transplanta-
tion for SCI.
Improved cell quality and safety, particularly with
respect to the risk of tumor-like overgrowth, will be
crucially important for any clinical use of hiPSC-NS/PCs.
Okada et al. (2005) revealed that the photon counts
measured by BLI analyses were significantly proportional
to the number of the transplanted cells in vivo. Nori et al.
(2015) indicated that some mice transplanted with
253G1 hiPSC-NS/PCs showed temporary motor function
recovery for up to 47 days after transplantation; however,658 Stem Cell Reports j Vol. 7 j 649–663 j October 11, 2016the photon counts of the transplanted cells increased
more than 10-fold from its initial value, and these mice
also developed tumor-like overgrowth and deterioration
of motor function at 103 days after transplantation. There-
fore, the photon counts measured by BLI analyses could be
useful for the diagnosis for detecting tumor-like over-
growth in the mouse injured spinal cords. In the present
study, the control group (i.e., the group without GSI pre-
treatment) showed a rapid increase in the photon count
of the transplanted cells and improvements in hindlimb
motor function, which subsequently deteriorated gradu-
ally upon long-term observations. However, in the GSI+
groups, the photon counts increased more slowly and
reached a plateau after transplantation. Greater functional
recovery was also observed, and was maintained at signifi-
cantly higher levels compared with the control group. In
addition, we previously reported that the size of the tumors
formed by the transplanted hiPSC-NS/PCs in the injured
spinal cord correlated with the proportion of Nestin+ cells
in the graft (Nori et al., 2015). The proportion of trans-
planted Nestin+ cells decreased from 10.7% ± 2.2% at
47 days to 7.5% ± 1.0% at 103 days after transplanting
201B7 hiPSC-NS/PCs, resulting in no tumor-like over-
growth. The proportion of Nestin+ cells increased from
19.6% ± 0.5% at 47 days to 33.1% ± 7.4% at 103 days after
transplanting 253G1 hiPSC-NS/PCs. Therefore, we suggest
that differentiation-resistant Nestin+ cells proliferated over
time and formed tumors. However, the present study
showed that the proportion of transplanted Nestin+ cells
in the control group increased to 30.3% ± 1.6% at
89 days after transplantation and resulted in tumor-like
overgrowth, whereas the proportion of Nestin+ cells in
the GSI+ group decreased to 5.3% ± 0.8% at 89 days after
transplantation and did not show evidence of tumor-like
overgrowth. The proportion of Ki-67+ cells in the control
group was significantly increased to 17.9% ± 0.9% at
89 days after transplantation compared with the GSI+
group. Furthermore, the proportion of pan-ELAVL (Hu)+
neuronal cells in the GSI+ groups significantly increased
to 51.0% ± 1.8% compared with the control group at
89 days after transplantation, although significant differ-
ences were not observed in glial differentiation. Most of
the GSI-pretreated, transplanted bIII-tubulin+/HNA+ cell-
derived neurons were co-localized with Bsn+ synaptic
boutons of the host neurons, and hSyn+ boutons were
apposed to bIII-tubulin+/HNA hostmouse neurons. These
findings indicate that the proportion of proliferating/
undifferentiating cells increases over time and induces tu-
mor-like overgrowth in the vertebral canal of the mice.
Therefore, the motor functional recovery observed in the
control group subsequently deteriorated gradually upon
long-term observations. However, pretreatment with GSI
differentiated nearly all of these cells into mature neurons,
which were further integrated into the reconstructed host
neuronal network, where they formed synapses and pre-
vented tumor-like overgrowth, even in mice transplanted
with the ‘‘bad’’ clone, after observations for long periods.
Therefore, significantly greater motor functional recovery
was maintained compared with the control group.
The activation of Notch1 has been found to contribute to
the invasion and metastasis of cancer via the EMT. In addi-
tion, Saad et al. (2010) showed that the overexpression of
NOTCH1 induces the expression of SNAIL. In the present
study, after GSI treatment the expression of NOTCH1,
SNAIL1, and SNAIL2was downregulated in vitro compared
with the control group. Furthermore, the proportion of
Notch1+, activated Notch1+, and Snail+ cells was also
significantly decreased after transplantation compared
with the control group, which indicated that the presence
of activated Notch1 on the transplanted cells reflected the
g-secretase-dependent activation of Notch1 in vivo. There-fore, the GSI pretreatment could reduce the acquisition of
EMTand inhibit the activation of Notch1 and Snail, which
induced the transplanted cells to undergo neuronal matu-
ration without tumor-like overgrowth upon transplanta-
tion of hiPSC-NS/PCs for SCI. However, Kopan and Ilagan
(2004) showed that other signaling molecules act as targets
for GSI. Thus, we cannot rule out the possibility that the
GSI-induced inhibition of other signaling pathways, such
as the expression of EMT-related genes, contributed to
these results.
Longer differentiation periods have been shown to
decrease the incidence of tumors. Alternatively, the selec-
tion of more mature cells using fluorescence-activated or
magnetic-activated cell sorting, introduction of suicide
genes, and irradiation of cells before transplantation may
also help inhibit tumor-like overgrowth. However,
these methods require long periods and more expensive
processes to prepare the donor cells. In contrast, GSI
pretreatment is a simple and inexpensive method that
could be useful for improving the safety of hiPSC-NS/PCs
transplantation therapy in SCI.
In conclusion, we confirmed that the GSI-treated hiPSC-
NS/PCs exhibited a reduced proportion of dividing cells
and increased neuronal maturation in vitro, and prevented
the tumor-like overgrowth of transplanted cells by in-
hibiting cell proliferation, thereby resulting in safe and
long-lasting functional recovery in vivo. Pretreatment of
hiPSC-NS/PCs with GSI can improve the safety of hiPSC-
NS/PC transplantation therapy for SCI.EXPERIMENTAL PROCEDURES
Cell Culture, hiPSC-NS/PC-Derived NS/PC Formation
Assay, Neuronal Differentiation Analyses, and
Lentiviral Transduction
The cell culture, hiPSC-NS/PC-derived NC/PC formation assay,
neuronal differentiation analyses of several human iPSCs, and
lentiviral transduction of neurospheres were performed as previ-
ously described (Nori et al., 2011, 2015; Okada et al., 2008). In
brief, three hiPSC-NS/PCs lines were dissociated and infected
with a lentivirus expressing ffLuc, a firefly luciferase fusion
protein under the control of the EF promoter, to enable the
detection of transplanted cells through their strong biolumines-
cent ffLuc signals in live SCI mice and in fixed spinal cord
sections. Detailed methods are described in Supplemental Exper-
imental Procedures.
Treatment of hiPSC-NS/PCs with GSI
One of the small-molecule GSIs, N-[N-(3,5-difluorophenacetyl)-l-
alanyl]-S-phenylglycine t-butyl ester (DAPT; Sigma-Aldrich), is a
potent nontransition-state analog inhibitor of g-secretase that is
thought to interact with the same active site between presenilin-1
heterodimers in g-secretase complexes. DAPT was dissolved
in DMSO at a final concentration of 10 mM. The highestStem Cell Reports j Vol. 7 j 649–663 j October 11, 2016 659
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concentration of this molecule that effectively inhibited the divi-
sion of hiPSC-NS/PCs without precipitating in culture medium
or producing toxic effects was determined in preliminary experi-
ments. The hiPSC-NS/PCs were cultured in vitro with GSI for
1 day in the GSI-1d group, 4 days in the GSI-4d group, andwithout
GSI in the control group. For the neuronal differentiation, prolifer-
ation, and cell transplantation assays, the hiPSC-NS/PCs were used
after the fifth passage.
Flow Cytometric Analyses
In the cell-cycle analyses, the hiPSC-NS/PCs were dissociated into
single cells and double immunofluorescence staining was per-
formed with the Click-iT Plus EdU Flow Cytometry Assay Kit
(Life Technologies). In the apoptosis analyses, double immunoflu-
orescence staining was performed using the primary antibodies
anti-allophycocyanin (APC)-labeled annexin V (561012) and
7-amino-actinomycin D (7-AAD, 559925) (BD Biosciences). The
cells were stained with a mixture of these primary antibodies for
15 min at 37C. Detailed methods are described in Supplemental
Experimental Procedures.
Microelectrode Array
The MEA was performed as previously described (Ko¨hling et al.,
2005), and detailed methods are provided in Supplemental Exper-
imental Procedures.
DNA Microarray Analyses
DNA microarray analyses were performed as previously described
(Parinya et al., 2014), and detailedmethods are provided in Supple-
mental Experimental Procedures. GO accessions are listed and
shown in Tables S1 and S2.
qRT-PCR
RNA isolation and RT-PCR were performed as previously described
(Nori et al., 2011, 2015; Okada et al., 2008), and detailed protocols
are provided in Supplemental Experimental Procedures.Figure 7. Long-Term Observations after Transplantation of GSI-P
(A) Quantitative analyses of the photon counts derived from the tra
n = 10 mice; GSI+ group, n = 10 mice).
(B) Representative images of mice at 0, 14, 28, 56, and 89 days after t
without GSI.
(C) Representative H&E-stained images of the spinal cords from each
(D) Representative immunohistological images of HNA+ cells, showing
1,000 mm.
(E) Graft volumes of the hiPSC-NS/PCs were measured and estimated f
(control group, n = 10 mice; GSI+ group, n = 10 mice).
(F) Comparison of the BMS scores among the PBS, control, and GSI+ gro
89 days after transplantation using the BMS score (PBS group, n = 10
(G) Comparison of the rotarod test among the PBS, control, and GS
plantation. Histograms show the total run time (PBS group, n = 10; c
(H) Comparison of the stride lengths among the PBS, control, and GS
transplantation using the DigiGait system. Histograms show the strid
10 mice).
*p < 0.05 and not significant (N.S.) according to the Wilcoxon rank-sum
Kramer test (F), or one-way ANOVA with the Tukey-Kramer test (G anSCI Animal Model and hiPSC-NS/PC Transplantation
Contusive SCI was induced at the level of the tenth thoracic spinal
vertebra in the spinal cords of adult female NOD-SCID mice. Nine
days after SCI, hiPSC-NS/PCs that had been pretreated with or
without GSI (5 3 105 cells/2 mL) were transplanted into the lesion
epicenter of each mouse. All experiments were performed in
accordance with the Guidelines for the Care and Use of Laboratory
Animals of Keio University (Assurance No. 13020) and the NIH
Guide for the Care and Use of Laboratory Animals. Detailed
methods are provided in Supplemental Experimental Procedures.
Histological Analysis
Histological analyses were performed at 89 days after transplanta-
tion. Spinal cord sections were histologically evaluated by H&E
staining and immunohistochemistry (IHC). Detailed protocols
are provided in Supplemental Experimental Procedures.
Behavioral Analyses
The motor function of each mouse in the PBS group, the control
group, and the GSI+ group was evaluated weekly for up to
98 days after injury using the BMS scores (Basso et al., 2006).
Detailed methods are provided in Supplemental Experimental
Procedures.
Statistical Analysis
All data are reported as mean ± SEM. AWilcoxon rank-sum test was
used to evaluate the differences between groups with respect to the
BLI analyses, H&E staining, and IHC results. One-way ANOVA
followed by the Tukey-Kramer test for multiple comparisons was
used to evaluate the differences in the following: number of living
cells; sphere size; flowcytometric analysesof thecell cycle/apoptosis
assays; neuronal differentiation analyses;MEA;DNAmicroarray an-
alyses; RT-PCRgene expressionprofile analyses; and the rotarod and
DigiGait results. Two-way repeated-measures ANOVA tests followed
by theTukey-Kramer testwereused for theBMSanalyses. pValuesof
<0.05 or <0.01 were considered to indicate statistical significance.retreated 201B7 hiPSC-NS/PCs
nsplanted cells until 89 days post transplantation (control group,
ransplantation of 201B7 hiPSC-NS/PCs that were pretreated with or
group at 89 days after transplantation. Scale bars, 1,000 mm.
a graft from each group at 89 days after transplantation. Scale bars,
or each group of SCI model animals at 89 days after transplantation
ups. Motor function in the hind limbs was assessed weekly for up to
; control group, n = 10; GSI+ group, n = 10 mice).
I+ groups. The rotarod test was performed at 89 days after trans-
ontrol group, n = 10; GSI+ group, n = 10 mice).
I+ groups. Treadmill gait analyses were performed at 89 days after
e lengths (PBS group, n = 10; control group, n = 10; GSI+ group, n =
test (A and E), two-way repeated-measures ANOVA with the Tukey-
d H). Data are presented as means ± SEM.
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